Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.62 |
| ▸ | DRD3 | P35462 | 1/20 | 0.62 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 3/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.46 |
| ▸ | CDK9 | P50750 | 1/20 | 0.46 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.42 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30499231 | 1.00 | DRD2 (0.62) | DRD2DRD3KCNH2CYP2D6SLC6A2 | |
| SCHEMBL25305365 | 1.00 | DRD2 (0.62) | DRD2DRD3KCNH2CYP2D6SLC6A2 | |
| Hydrochloric Acid SCHEMBL567646 | 0.98 | DRD2 (0.60) | DRD2DRD3KCNH2CYP2D6SLC6A2 | |
| SCHEMBL31158728 | 0.91 | DRD2 (0.51) | DRD2DRD3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13975332 | 0.91 | DRD2 (0.51) | DRD2DRD3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL10126278 | 0.91 | DRD2 (0.51) | DRD2DRD3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3648147 | 0.91 | DRD2 (0.51) | DRD2DRD3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL31159074 | 0.91 | DRD2 (0.51) | DRD2DRD3SLC6A2SLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL3646555 | 0.90 | HTR2C (0.51) | DRD2DRD3SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL20757695 | 0.83 | CHRNB2 (0.53) | DRD2DRD3SLC6A2SLC6A3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227428-A1 | AMIDO COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2023-07-20 | — | — | US | disclosed |
| US-20230227428-A1 | AMIDO COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2023-07-20 | — | — | US | disclosed |
| US-20230227428-A1 | AMIDO COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2023-07-20 | — | — | US | disclosed |
| US-11345679-B2 | Quaternary lactam compound and pharmaceutical use thereof | SHANGHAI MEIYUE BIOTECH DEVELOPMENT CO., LTD. (CN) | 2022-05-31 | — | — | US | disclosed |
| WO-2021253098-A1 | AMIDO COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2021-12-23 | — | — | WO | disclosed |
| EP-3778588-A1 | QUATERNARY LACTAM COMPOUND AND PHARMACEUTICAL USE THEREOF | Shanghai Meiyue Biotech Development Co., Ltd. (CN) | 2021-02-17 | — | — | EP | disclosed |
| US-20210032219-A1 | QUATERNARY LACTAM COMPOUND AND PHARMACEUTICAL USE THEREOF | SHANGHAI MEIYUE BIOTECH DEVELOPMENT CO., LTD. (CN) | 2021-02-04 | — | — | US | disclosed |
| WO-2019185046-A1 | QUATERNARY LACTAM COMPOUND AND PHARMACEUTICAL USE THEREOF | 上海美悦生物科技发展有限公司 | 2019-10-03 | — | — | WO | disclosed |
| CN-103857670-B | 2-oxo-piperidinyl derivatives | UCB PHARMA S.A. (BE) | 2016-03-23 | — | — | CN | disclosed |
| EP-2909170-A1 | SUBSTITUTED CARBAMATE COMPOUNDS AND THEIR USE AS TRANSIENT RECEPTOR POTENTIAL (TRP) CHANNEL ANTAGONISTS | F. Hoffmann-La Roche AG (CH) | 2015-08-26 | — | — | EP | disclosed |
| CN-102282138-A | Inhibitors of diacylglycerol acyltransferase | — | 2011-12-14 | — | — | CN | disclosed |
| US-20110224136-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | MERCK SHARP & DOHME CORP | 2011-09-15 | — | — | US | disclosed |
| EP-2346853-A2 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | Schering Corporation (US) | 2011-07-27 | — | — | EP | disclosed |
| CN-101842369-A | 2, 3-dihydrobenzo [1, 4] dioxin-2-ylmethyl derivatives as alpha 2C antagonists for the treatment of peripheral and central nervous system disorders | ORION CORP | 2010-09-22 | — | — | CN | disclosed |
| US-20100216836-A1 | 2,3-DIHYDROBENZO(1,4) DIOXIN-2-YLMETHYL DERIVATIVES AS ALPHA2C ANTAGONISTS FOR USE IN THE TREATMENT OF PERIPHERIC AND CENTRAL NERVOUS SYSTEME DISEASES | ORION CORPORATION (FI) | 2010-08-26 | — | — | US | disclosed |
| WO-2010071575-A1 | QUATERNARY PIPERIDINE DERIVATIVES AND USES THEREOF | ASTRAZENECA AB (SE) | 2010-06-24 | — | — | WO | disclosed |
| WO-2010059606-A2 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | SCHERING CORPORATION (US) | 2010-05-27 | — | — | WO | disclosed |
| EP-2176252-A1 | 2, 3-DIHYDROBENZO[1, 4]DIOXIN-2-YLMETHYL DERIVATIVES AS ALPHA2C ANTAGONISTS FOR USE IN THE TREATMENT OF PERIPHERIC AND CENTRAL NERVOUS SYSTEME DISEASES | ORION CORPORATION (FI) | 2010-04-21 | — | — | EP | disclosed |
| WO-2009013390-A1 | 2, 3-DIHYDROBENZO[1, 4] DIOXIN-2-YLMETHYL DERIVATIVES AS ALPHA2C ANTAGONISTS FOR USE IN THE TREATMENT OF PERIPHERIC AND CENTRAL NERVOUS SYSTEME DISEASES | ORION CORPORATION (FI) | 2009-01-29 | — | — | WO | disclosed |
| US-20080176883-A1 | Antiinflammtory, antiproliferative, anticancer agents; (3-Hydroxy-pyrrolidin-1-yl)-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone | ABBVIE INC. | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176883-A1 | Antiinflammtory, antiproliferative, anticancer agents; (3-Hydroxy-pyrrolidin-1-yl)-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone | MIF, CCL5, CCR2 | DRD2 1732/4885DRD3 2047/4885KCNH2 4222/4885 |
| US-20110224136-A1 | INHIBITORS OF DIACYLGLYCEROL ACYLTRANSFERASE | DGAT2, DGAT1, LCAT | DRD2 1364/4885DRD3 1619/4885KCNH2 3376/4885 |
| US-20230227428-A1 | AMIDO COMPOUNDS | RIPK1, RIPK3, MLKL | DRD2 3854/4885DRD3 3305/4885KCNH2 4047/4885 |
| US-20210032219-A1 | QUATERNARY LACTAM COMPOUND AND PHARMACEUTICAL USE THEREOF | F2, PCSK9, F9 | DRD2 3852/4885DRD3 4141/4885KCNH2 2362/4885 |
| US-11345679-B2 | Quaternary lactam compound and pharmaceutical use thereof | F2, PCSK9, F9 | DRD2 3852/4885DRD3 4141/4885KCNH2 2362/4885 |
| US-20100216836-A1 | 2,3-DIHYDROBENZO(1,4) DIOXIN-2-YLMETHYL DERIVATIVES AS ALPHA2C ANTAGONISTS FOR USE IN THE TREATMENT OF PERIPHERIC AND CENTRAL NERVOUS SYSTEME DISEASES | PMP22, NPY2R, ADRA2C | DRD2 277/4885DRD3 356/4885KCNH2 663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.